Hormone Replacement Trial Against ALzheimers' Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age40-65
SponsorUniversity Hospital, Ghent
About this trial
The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid.
The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy.
Postmenopausal women with and without history of breast cancer will be recruited for the trial.
Eligibility criteria
Qualifiers
postmenopausal women
40 - 65 years
Disqualifiers
Longer than 10 years in menopause
thyroid dysfunction
hypertension
medical history of psychiatric comorbidity
Trial design
Treatments tested in this trial
- blood take
Treatment groups
600 Participants
are divided into 10 treatment groups10
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov